Hengrui Pharmaceutical (600276.SH): SHR-A1904 for injection included in the list of breakthrough treatment varieties

Zhitongcaijing · 1d ago

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company and its subsidiary Shanghai Hengrui Pharmaceutical Co., Ltd.'s injectable SHR-A1904 were included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration. The intended indication (or functional treatment) of this drug: CLDN 18.2 positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with previous treatment at least first-line system treatment.